Primer: Celltrion (068270 KP) - Nov 2025
Celltrion is strategically transitioning from a biosimilar powerhouse to a global innovative biopharmaceutical company, underscored by the...
207 Views
Celltrion (068270 KS/Buy)Cost Ratio Continues to Improve
Our target price for Celltrion is based on our 12-month forward EBITDA estimate of W1.87tr and a target EV/EBITDA of 27x.
258 Views
Celltrion Inc Update – Is It Time to Go Long (068270 KS)
​Celltrion Inc has underperformed due to biosimilar hype, but outlook for next 5 years is promising with revenue target market value expected to...
628 Views
APAC Healthcare Weekly (July 26) – Hengrui, BeOne, Takeda, Nippon Shinyaku, Samsung Bio, Celltrion
Hengrui’s camrelizumab got indication expansion approval for cervical cancer. BeOne announced $300M expansion plan for US facility. Samsung...
132 Views
APAC Healthcare Weekly (July 19) – Kelun Bio, CSPC Pharma, Insilico, Eisai, Celltrion, Mesoblast
Kelun Biotech’s sac-TMT met primary endpoint in Phase 3 trial. FDA approves Eisai’s Leqembi Iqlik for Alzheimer’s starting therapy. Mesoblast met...
125 Views